Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Baseline characteristics of the participants. | ACEI/ARB | | | Non-user | User | | Variable | n = 1,986 | n = 1,290 | P-value: Vitamin D receptor activators | | | 0.53
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Observational study.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The MBD-5D study is a multicenter, 3-year, prospective, observational study involving maintenance hemodialysis patients with secondary hyperparathyroidism.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients
Observational study · PLoS ONE · 2015
Original publication title
Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients
© 2015 Yamamoto et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Patients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS inhibitors reduces the incidence of fracture in hemodialysis patients.
Source: BackgroundAbstract: Methods and Findings
This was a multicenter, 3-year, prospective, observational study. From 2008 to 2011, maintenance hemodialysis patients with secondary hyperparathyroidism (N = 3,276) treated with angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) at baseline were followed for a mean of 2.7 years. The association between the use of ACEI/ARB and hospitalization rate owing to fracture was examined by using Cox regression models. Effect modifications by the severity of secondary hyperparathyroidism (intact parathyroid hormone [iPTH] level), sex, and systolic blood pressure were also examined.
The incidence proportion of fracture-related hospitalization was 5.42% throughout the observation period. ACEI/ARB use was associated with a lower rate of fracture-related hospitalization (adjusted hazard ratio, 0.65; 95% confidence interval [CI], 0.45 to 0.92). This association was not significantly affected by sex (P = 0.56) or systolic blood pressure levels (P = 0.87). The hazard ratios adjusted by iPTH levels were qualitatively different, but not statistically significant (P = 0.11): 0.77 (95% CI, 0.42 to 1.39), 0.38 (95% CI, 0.20 to 0.73), 0.59 (95% CI, 0.29 to 1.21), and 1.29 (95% CI, 0.58 to 2.42) for the first, second, third and fourth quartiles of iPTH, respectively.
Source: Methods and FindingsAbstract: Conclusions
Use of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.
Source: ConclusionsAuthors’ abstract
Background
Patients with chronic kidney disease, especially those undergoing dialysis treatment and having secondary hyperparathyroidism, have a high risk of bone fracture. The renin-angiotensin system (RAS) is associated with osteoclastic bone resorption. We aimed to examine whether the use of RAS inhibitors reduces the incidence of fracture in hemodialysis patients.
Methods and Findings
This was a multicenter, 3-year, prospective, observational study. From 2008 to 2011, maintenance hemodialysis patients with secondary hyperparathyroidism (N = 3,276) treated with angiotensin converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) at baseline were followed for a mean of 2.7 years. The association between the use of ACEI/ARB and hospitalization rate owing to fracture was examined by using Cox regression models. Effect modifications by the severity of secondary hyperparathyroidism (intact parathyroid hormone [iPTH] level), sex, and systolic blood pressure were also examined.
The incidence proportion of fracture-related hospitalization was 5.42% throughout the observation period. ACEI/ARB use was associated with a lower rate of fracture-related hospitalization (adjusted hazard ratio, 0.65; 95% confidence interval [CI], 0.45 to 0.92). This association was not significantly affected by sex (P = 0.56) or systolic blood pressure levels (P = 0.87). The hazard ratios adjusted by iPTH levels were qualitatively different, but not statistically significant (P = 0.11): 0.77 (95% CI, 0.42 to 1.39), 0.38 (95% CI, 0.20 to 0.73), 0.59 (95% CI, 0.29 to 1.21), and 1.29 (95% CI, 0.58 to 2.42) for the first, second, third and fourth quartiles of iPTH, respectively.
Conclusions
Use of RAS inhibitors is associated with a lower rate of fracture-related hospitalization in hemodialysis patients with secondary hyperparathyroidism.
Trial Registration
ClinicalTrials.gov NCT00995163
Publication and source details
Original title: Use of Renin-Angiotensin System Inhibitors Is Associated with Reduction of Fracture Risk in Hemodialysis Patients
Suguru Yamamoto; Ryo Kido; Yoshihiro Onishi; Shingo Fukuma; Tadao Akizawa; Masafumi Fukagawa; Junichiro J. Kazama; Ichiei Narita; Shunichi Fukuhara
PLoS ONE · 2015
Competing Interests: The MBD-5D study was supported by research grants from Kyowa Hakko Kirin. M. F. has acted as a consultant, received honoraria, and grants (research support) from Kyowa Hakko Kirin. T. A. has acted as a consultant and received grants (research support) from Kyowa Hakko Kirin, besides of being a member of the speakers’ bureau at Kyowa Hakko Kirin. S. F. has acted as a scientific advisor for Kyowa Hakko Kirin, and has received grants (research support) from Kyowa Hakko Kirin.
The other authors have no conflicts of interest to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: SY RK YO S. Fukuma TA MF JK IN S. Fukuhara. Performed the experiments: SY RK YO S. Fukuma TA MF S. Fukuhara. Analyzed the data: SY RK YO S. Fukuma S. Fukuhara. Contributed reagents/materials/analysis tools: TA MF S. Fukuhara. Wrote the paper: SY RK YO S. Fukuma TA MF JK IN S. Fukuhara.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T20:31:21.767333+00:00
DOI: 10.1371/journal.pone.0122691 · PMC4395204